Earnings summaries and quarterly performance for Cryoport.
Executive leadership at Cryoport.
Jerrell Shelton
Detailed
Chairman, President and Chief Executive Officer
CEO
EZ
Edward Zecchini
Detailed
Senior Vice President and Chief Digital and Technology Officer
MS
Mark Sawicki
Detailed
Senior Vice President and Chief Scientific Officer
RS
Robert Stefanovich
Detailed
Senior Vice President, Chief Administrative Officer and Chief Financial Officer
Board of directors at Cryoport.
Research analysts who have asked questions during Cryoport earnings calls.
David Larsen
BTIG
4 questions for CYRX
Also covers: ACCD, AGL, AMWL +19 more
KC
Kyle Crews
UBS
4 questions for CYRX
Also covers: CERT, MEDP, MRVI
MS
Matthew Stanton
Jefferies
4 questions for CYRX
Also covers: AZTA, BLFS, CDXS +5 more
PS
Puneet Souda
Leerink Partners
4 questions for CYRX
Also covers: A, ABCL, BRKR +20 more
Paul Knight
KeyBanc Capital Markets
3 questions for CYRX
Also covers: A, AZTA, BLFS +13 more
DS
David Saxon
Needham & Company
2 questions for CYRX
Also covers: ALC, ALGN, ATEC +11 more
RB
Richard Baldry
ROTH MKM
2 questions for CYRX
Also covers: AEYE, ASUR, EGAN +9 more
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for CYRX
Also covers: AKYA, BRKR, CSTL +15 more
AS
Anna Snopkowski
KeyBanc Capital Markets
1 question for CYRX
Also covers: BLFS, RGEN, TKNO
JS
Jenny Shen
TD Cowen
1 question for CYRX
Also covers: AGL, CCSI, DCGO +8 more
Mac Etoch
Stephens Inc.
1 question for CYRX
Also covers: AZTA, RGEN, STE +5 more
TS
Tejas Savant
Morgan Stanley
1 question for CYRX
Also covers: ADPT, AKYA, AVTR +19 more
YT
Yih-Ming Tu
Morgan Stanley
1 question for CYRX
Also covers: CTKB
Recent press releases and 8-K filings for CYRX.
Cryoport Reports Strong Q3 2025 Revenue Growth and Updates Full-Year Guidance
CYRX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Cryoport's total revenue from continuing operations for Q3 2025 increased 15% year-over-year to $44.2 million, primarily driven by a 36% year-over-year rise in Commercial Cell & Gene Therapy revenue to $8.3 million.
- The company updated its full-year 2025 revenue guidance from continuing operations to a range of $170.0 million to $174.0 million.
- For Q3 2025, Cryoport reported a net loss attributable to common stockholders of $8.9 million, or $0.18 per share, and its Adjusted EBITDA from continuing operations was a negative $0.6 million, an improvement from a negative $2.7 million in Q3 2024.
- As of September 30, 2025, Cryoport held $421.3 million in cash, cash equivalents, and short-term investments.
Nov 4, 2025, 10:18 PM
Cryoport Reports Strong Q3 2025 Revenue Growth and Nears Profitability
CYRX
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Cryoport reported double-digit revenue growth in Q3 2025 across both its Life Sciences Services and Life Sciences Products segments, with commercial cell and gene therapy support revenue increasing 36% year-over-year to $8.3 million and biostorage bioservices revenue growing 21%.
- The company is nearing profitability, reporting an adjusted EBITDA loss of $600,000 in Q3 2025 and positive cash flow from operating activities of $2.2 million for the quarter, with management expecting to reach positive adjusted EBITDA as early as year-end.
- Strategic investments include the recent opening of the logistics portion of a new Global Supply Chain Center in Paris, France, and plans for another center in Santa Ana, California, by the second half of 2026, alongside the launch of new MVE Biological Solutions vapor shippers.
- Management anticipates continued high single-digit growth for the MVE product segment and robust growth in bioservices into 2026, driven by market stability and ongoing advancements in cell and gene therapies.
Nov 4, 2025, 10:00 PM
Global Clinical Trial Supply and Logistics Market Projected for Significant Growth
CYRX
M&A
Revenue Acceleration/Inflection
New Projects/Investments
- The global clinical trial supply and logistics market was valued at USD 3.98 billion in 2024 and is expected to exceed USD 8.45 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 7.84% from 2025 to 2034.
- In 2024, North America held the largest market share at 36%, and the pharmaceuticals segment accounted for the biggest share by end-user at 42.22%.
- Key drivers for market growth include the increasing adoption of decentralized and virtual clinical trials, rising demand for cold chain logistics, and the integration of advanced tracking and visibility technologies.
- A significant recent development in the market is DHL Group's acquisition of CRYOPDP from Cryoport Inc. in March 2025, which aims to expand DHL's life sciences and healthcare supply chain capabilities.
Sep 2, 2025, 1:00 PM
Cryoport completes CRYOPDP divestiture and strategic partnership with DHL
CYRX
M&A
- Cryoport completed the CRYOPDP divestiture to DHL Group on June 11, 2025, receiving approximately $200 million in cash consideration.
- The transaction terms included a $133 million cash purchase price and $77.2 million in intercompany loan repayment, strengthening Cryoport’s capital position.
- Cryoport entered a strategic partnership with DHL to enhance global temperature-controlled supply chain solutions for the life sciences and healthcare sectors.
- The expanded service offering focuses on the APAC and EMEA regions, supporting Cryoport’s growth trajectory and goal of sustainable, long-term profitability.
Jun 13, 2025, 12:00 AM
Cryoport Reports Q1 2025 Financial Performance and Strategic Updates
CYRX
Earnings
Revenue Acceleration/Inflection
Product Launch
Guidance Update
M&A
- Revenue from continuing operations reached $41.0 million in Q1 2025, reflecting a 10% year-over-year increase with Life Sciences Services contributing 56% of total revenue
- Commercial Cell & Gene therapy revenue grew 33% YoY, supporting 711 global clinical trials and advancing the regenerative medicine sector
- Strategic partnership with DHL announced, including the divestiture of CRYOPDP for $195 million (expected to close in Q2/Q3 2025) to strengthen global market reach and the financial profile
- Product revenue stabilized with modest 2% YoY growth, aided by new launches such as the HV3 and HE 800
May 7, 2025, 9:01 PM
Cryoport & DHL: Acquisition, Strategic Update & FY25 Guidance
CYRX
M&A
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- DHL Group acquired 100% of CRYOPDP in an all-cash transaction valued at $195M, strengthening its specialized logistics for life sciences and healthcare
- Strategic Partnership with DHL Group supports DHL’s Strategy 2030, enhancing its Pharma Specialized Network for clinical trials, biopharma, and cell & gene therapies
- Global Capability Expansion: The acquisition bolsters Cryoport’s market position across APAC and EMEA, driving growth in supply chain solutions
- FY25 Revenue Guidance: Projected revenues between $165.0M–$173.0M with 6%-10% YoY growth, excluding first-quarter CRYOPDP contributions
- Enhanced Financial Profile: FY24 gross margins reached 44.5% actual (46.1% pro forma), with the deal expected to boost pro forma cash to over $450M
Mar 31, 2025, 1:06 PM
Cryoport Q4 & FY 2024 Financial Results and Earnings Call Overview
CYRX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- FY 2024 revenue reached $228.4 million with Q4 revenue of $59.5 million; Life Sciences Services now represent 67% of total revenue (up from 62%) .
- Q4 gross margin improved to 45.8% from 40.6%, reflecting effective cost management .
- Commercial Cell & Gene Therapy revenue grew by 37% in Q4 and 20% for FY 2024, driven by multiple commercial approvals and expanding clinical trial support .
- Supported a record 701 global clinical trials, underscoring robust operational performance .
- Launched IntegriCell with early Q1 contracts and anticipated significant impact in 2026 .
- Provided 2025 revenue guidance of $240‑$250 million while outlining ongoing cost reduction and profitability initiatives .
Mar 4, 2025, 9:10 PM
Quarterly earnings call transcripts for Cryoport.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more